LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Rhythm Pharmaceuticals Inc

Cerrado

SectorSanidad

101.36 1.73

Resumen

Variación precio

24h

Actual

Mínimo

98.76

Máximo

101.36

Métricas clave

By Trading Economics

Ingresos

2.9M

-47M

Ventas

16M

49M

Margen de beneficios

-96.144

Empleados

283

EBITDA

6.9M

-40M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+12.34% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

896M

6.9B

Apertura anterior

99.63

Cierre anterior

101.36

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

117 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 sept 2025, 23:37 UTC

Acciones populares

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sept 2025, 20:41 UTC

Ganancias

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sept 2025, 20:30 UTC

Ganancias

GameStop 2Q Sales, Profit Rise

9 sept 2025, 23:19 UTC

Charlas de Mercado

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sept 2025, 21:35 UTC

Ganancias

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 21:32 UTC

Ganancias

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sept 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 sept 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sept 2025, 20:26 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:23 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:12 UTC

Ganancias

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sept 2025, 20:07 UTC

Ganancias

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Software Revenue $5.72B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Rev $14.93B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q EPS $1.01 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Synopsys 3Q EPS $1.50 >SNPS

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Services Revenue $1.35B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Adj EPS $1.47 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Hardware Revenue $670M >ORCL

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

12.34% repunte

Estimación a 12 Meses

Media 112.08 USD  12.34%

Máximo 135 USD

Mínimo 95 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

13

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

117 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat